(Sharecast News) - Novo Nordisk said on Tuesday that it has agreed to buy the rights to a Hengrui Pharma weight-loss drug for up to $2.6bn.
The license agreement with China's Hengrui is for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE